Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp
Bullboard Posts
User Avatar Image
(4)
•••
Comment by bazooka73on Jun 10, 2020 10:34am
106 Views
Post# 31133052

RE:RE:Time for SBM to push something across the finish line

RE:RE:Time for SBM to push something across the finish line
MirrorWorldMan wrote: This also came out of Howie's PR on in March 2020:

    "Other exciting news is anticipated regarding TFC-039 as stated in our last update. Extensive progress has been made and an announcement is anticipated. We are fortunate to have ample working capital to achieve our goals and are in no need to contemplate any dilutive capital raise"

 And as a stated 12 month milestone on the 'latest' investor presentation:
  •  Find additional licensing partners for the SGLT2 Inhibitor
Where is all this extensive progress?  And does extensive progress come with any numbers, or just more rhetoric?



The statement regarding SGLT2 in the really latest investor presentation is as follows:

• Complete an additional licensing agreement for the SGLT2 inhibitor in new markets
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities